INTS6L: A Potential Drug Target for Fibrosis and Cancer (G203522)

Target Name: INTS6L

NCBI ID: G203522

INTS6L

INTS6L: A Potential Drug Target for Fibrosis and Cancer

INTS6L (Integrin alpha-2, also known as DDX26B), is a protein that is expressed in many different tissues and cells in the body. It is a member of the integrin family, which is a large group of transmembrane proteins that play a variety of roles in cell-cell and cell-extracellular matrix interactions.

INTS6L is a 21-kDa protein that is expressed in many different tissues, including the brain, heart, liver, and pancreas. It is predominantly expressed in the liver, where it is involved in the production of collagen, a protein that is important for the structure and integrity of tissues.

One of the unique features of INTS6L is its ability to interact with the protein FN1 (fibrillin-1), which is also known as PDGF-BB (Platelet-derived growth factor-BB). FN1 is a potent growth factor that is involved in many different processes in the body, including cell growth, differentiation, and angiogenesis.

INTS6L has been shown to play a role in the regulation of FN1 signaling in the liver. Studies have shown that INTS6L can interact with FN1 and that this interaction can modulate the activity of FN1 in a variety of ways.

One of the potential implications of this interaction is that INTS6L may be a drug target or biomarker for diseases that are characterized by the over-activation of FN1 signaling. For example, INTS6L has been shown to be involved in the development of fibrosis, a condition in which tissues become stiff and difficult to move. Fibrosis is often caused by the activation of FN1 signaling, which leads to the production of extracellular matrix (ECM) components and the loss of tissue flexibility.

INTS6L may also be a biomarker for other diseases that are characterized by the over-activation of FN1 signaling. For example, INTS6L has been shown to be involved in the development of cancer, particularly liver cancer. Cancer is often caused by the activation of FN1 signaling, which leads to the production of ECM components and the loss of tissue normalization.

Another potential implication of INTS6L's involvement in FN1 signaling is its potential as a therapeutic target. By inhibiting the activity of FN1, INTS6L may be able to reduce the production of ECM components and improve tissue flexibility in a variety of diseases.

In conclusion, INTS6L is a protein that is expressed in many different tissues and cells in the body and is involved in the production of collagen and the regulation of FN1 signaling. Its involvement in these processes makes it a potential drug target or biomarker for a variety of diseases that are characterized by the over-activation of FN1 signaling. Further research is needed to fully understand the role of INTS6L in these processes and to develop effective therapies based on its properties.

Protein Name: Integrator Complex Subunit 6 Like

The "INTS6L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INTS6L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets